Incretin Effect
The incretin effect describes the observation that oral glucose ingestion stimulates significantly greater insulin secretion than an equivalent intravenous glucose load. This enhancement is mediated by incretin hormones — primarily GLP-1 and GIP — released from intestinal cells in response to nutrient ingestion.
Incretin-based peptides exploit this pathway: semaglutide mimics GLP-1, tirzepatide mimics both GIP and GLP-1, and retatrutide additionally engages the glucagon receptor. The incretin effect accounts for an estimated 50-70% of postprandial insulin secretion in healthy individuals.
All Healthy Aminos products are for research use only.
Related Products
Related Terms
GLP-1 Receptor
A class B G-protein coupled receptor activated by glucagon-like peptide-1 and its analogs, central to incretin signaling research.
GIP Receptor
A G-protein coupled receptor for glucose-dependent insulinotropic polypeptide, targeted by dual and triple incretin agonists.
Receptor Agonist
A molecule that binds to and activates a receptor, mimicking the action of the natural ligand to initiate a signaling response.
Research Use Only
FOR RESEARCH USE ONLY. Products sold by Healthy Aminos are intended strictly for in-vitro research and laboratory use. Not for human or animal consumption. Not FDA approved. By purchasing from Healthy Aminos, the buyer acknowledges that these products are not intended to diagnose, treat, cure, or prevent any disease. All products are sold as reference standards and research chemicals only.